CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma
Dr. Levine on the PARP Inhibitor Landscape for Ovarian Cancer
Dr. Oyer on Tools for Clinicians to Use When Treating Patients With Cancer
Oncology Conference Articles
Abemaciclib Active in HR+/HER2- Breast Cancer Patients With Brain Mets
Preliminary evidence suggests that abemaciclib penetrated brain metastases and had antitumor activity in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Rituximab/Lenalidomide Combo Shows Promise for Indolent Lymphomas
Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.
Maintenance Olaparib Shows Promise in Platinum-Sensitive Serous Ovarian Cancer
The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.
Ovarian Cancer Landscape Evolving With Encouraging SOLO2 Analyses, Novel Agents
Michael J. Birrer, MD, PhD, discusses some of the exciting data presented at the 2017 ASCO Annual Meeting, especially with olaparib (Lynparza) in SOLO2, and what other emerging advancements are poised to transform the landscape.
Enasidenib Shows Strong Activity in AML
Results from a phase I/II study demonstrated that enasidenib (AG-221) is well-tolerated and associated with a median overall survival of more than 9 months in patients with IDH2-mutated relapsed/refractory acute myeloid leukemia.
Mirvetuximab Soravtansine Shows Promise in Ovarian Cancer
Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853) induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.
ASCO Partners With FDA to Incorporate Real-World Evidence Into Drug Decisions
In recognition of the potential for real-world evidence to significantly improve the way patients with cancer are treated, CancerLinQ has formed new partnerships with the US government that are expected to coordinate the sharing of patient data and incorporate that information into the FDA regulatory process.
Study Further Characterizes Niraparib PFS Benefit in Ovarian Cancer
Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline
mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.
Osimertinib Improves Response in T790M+ NSCLC With CNS Metastases
Patients with T790M-positive non–small cell lung cancer had superior outcomes when treated with osimertinib (Tagrisso) for central nervous system metastases, according to phase III results presented at the 2017 ASCO Annual Meeting.
Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian Cancer
In follow-up results to data first presented in December 2016, investigators found that the combination of olaparib (Lynparza) and cediranib maleate continued to show superior progression-free survival compared with olaparib alone for women with BRCA-negative recurrent platinum-sensitive ovarian cancer.
Marrow Clearance With Concurrent CAR T-Cells, Ibrutinib in Resistant CLL
Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia, results of a pilot study showed.
Avelumab/Axitinib Combo Shows Promise in Frontline RCC
Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) as a frontline regimen induced a response rate of 58.2% in patients with advanced renal cell carcinoma, according to findings from the phase Ib JAVELIN Renal 100 trial presented at the 2017 ASCO Annual Meeting.
Pembrolizumab/ Epacadostat Combo Active in Urothelial Carcinoma
Combining the PD-1 inhibitor pembrolizumab with the IDO1 inhibitor epacadostat led to an overall response rate of 35% in patients with advanced urothelial carcinoma.
Epacadostat/ Nivolumab Shows Promising Efficacy for Melanoma, Head and Neck Cancer
The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.
BCMA CAR T-Cell Therapy Yields High Remission Rate in Multiple Myeloma
Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.
Dacomitinib Bests Gefitinib in EGFR-Mutant NSCLC
Dacomitinib, a second-generation EGFR inhibitor, reduced the risk of disease progression by more than 40% and resulted in an average 6.5-month improvement in response duration compared with gefitinib (Iressa) as a first-line treatment for patients with advanced,
-mutant non–small cell lung cancer.
Adjuvant Pertuzumab May Help Some Early Breast Cancer Patients
The addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer slightly improved the rate of recurrence overall but had a greater benefit for individuals with higher-risk disease, particularly as more time elapsed, according to early results from the phase III APHINITY trial.
Nintedanib Chemo Combo Promising for Malignant Mesothelioma
Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free survival by 3.7 months for chemotherapy-naive patients with malignant pleural mesothelioma, according to data reported at the 2017 ASCO Annual Meeting.
Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in Mesothelioma
Nivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.
Alectinib Delayed Progression, Reduced Risk for Death by 53% in ALK+ NSCLC
In patients with ALK-positive non-small cell lung cancer, the second-generation TKI inhibitor alectinib (Alecensa) delayed progression by an additional 15 months compared with the standard-of-care crizotinib (Xalkori).
Pembrolizumab Again Demonstrates Durable Activity in TNBC
Pembrolizumab (Keytruda) showed durable antitumor activity in patients with heavily pretreated metastatic triple-negative breast cancer (TNBC), according to findings from cohort A of the phase II KEYNOTE-086 trial presented at the 2017 ASCO Annual Meeting.
Pembrolizumab Gastric Cancer Data Updated, as FDA Considers Approval
Pembrolizumab continued to show promising signs of clinical activity as a treatment for patients with advanced gastric or gastroesophageal junction cancer in updated findings from the KEYNOTE-059 study.
Nivolumab/Ipilimumab Highly Active in Patients With Melanoma Brain Metastases
Nivolumab plus ipilimumab demonstrated an intracranial response rate of 42% in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Lenalidomide Consolidation OS Plateau Intrigues in CLL
Induction therapy with fludarabine and rituximab followed by lenalidomide consolidation therapy (FR-L) demonstrated a distinct plateau in overall survivalbeyond that seen with FR or FR plus cyclophosphamide (FCR) alone for patients with symptomatic, untreated non-del(11q) chronic lymphocytic leukemia.
Patients With Advanced Cancer Live Longer When They Report Symptoms Online and in Real Time
Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring, according to findings of a randomized trial reported at the 2017 ASCO Annual Meeting.
Study Backs 50% Chemo Cutback After Surgery for Low-Risk Colon Cancer
Most patients with low-risk advanced colon cancer would benefit from a 50% reduction in the oxaliplatin-containing chemotherapy they typically receive after surgery without notably increasing their risk of recurrence and while markedly decreasing the likelihood that they will develop neuropathy, according to an analysis that challenges the current standard of care and paves the way for a more personalized approach.
Lenvatinib OS Noninferior, PFS Improved Versus Sorafenib for Unresectable HCC
First-line treatment with lenvatinib (Lenvima) improved progression-free survival by 3.7 months and was noninferior for overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma.
Olaparib Extends PFS in Phase III BRCA+ Breast Cancer Trial
The PARP inhibitor olaparib (Lynparza) reduce the risk of disease progression by 42% versus standard chemotherapy in patients with
-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.
Pembrolizumab/Entinostat Active in Melanoma Patients Refractory to Checkpoint Inhibitors
Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the HDAC inhibitor entinostat demonstrated promising clinical activity and acceptable safety in patients with melanoma who were refractory to immune checkpoint inhibitors.
Ublituximab/Ibrutinib Shows High ORR for High-Risk CLL
The combination of ublituximab and ibrutinib demonstrated an objective response rate of 78% for patients with previously treated high-risk chronic lymphocytic leukemia.
Genomic Profiling Yields OS Benefit for Patients With Targeted Therapy Matches
Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine.
Larotrectinib Yields Impressive Responses Across All Age Groups and Tumor Types Harboring TRK Fusion Mutations
Three out of 4 patients representing a range of TRK fusion–positive solid tumors responded to the novel pan-TRK inhibitor larotrectinib (LOXO-101) and remain on treatment, setting the stage for the well-tolerated oral agent to become a standard of care for adults and children with any advanced tumor harboring this mutation.
Abemaciclib Extends PFS in Phase III Breast Cancer Trial
Adding the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression or death by 45% versus fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer, according to findings presented at the 2017 ASCO Annual Meeting.
Pembrolizumab/Chemo PFS Benefit in NSCLC Sustained With Longer Follow-Up
The frontline combination of pembrolizumab, pemetrexed, and carboplatin reduced the risk of progression or death by 50% and nearly doubled objective response rates compared with chemotherapy alone for patients with advanced non-squamous NSCLC.
Novel Sequencing Approach Detects Circulating Tumor DNA in 89% of Patients with Advanced Cancer
A new, high-intensity genomic sequencing approach for circulating tumor DNA uncovered at least 1 genetic change in both the tumor DNA and the blood of 89% of patients, demonstrating a high rate of concordance between 2 approaches for detecting molecular aberrations, according to a study presented at the 2017 ASCO Annual Meeting.
Abiraterone Studies Hailed as Practice-Changing in Newly Diagnosed Metastatic Prostate Cancer
Earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by nearly 40% for men with high-risk advanced or metastatic prostate cancer who were newly diagnosed or had not yet received hormone therapy in findings from 2 clinical trials presented at the 2017 ASCO Annual Meeting.
Pregnancy Does Not Increase Recurrence Risk of Early-Stage, ER-Positive Breast Cancer
Women who have had early breast cancer, along with their doctors, often worry that pregnancy could cause disease recurrence. But according to the results of a new study, that’s not the case.
Web-Based Therapy Helps Newly Diagnosed Patients Manage Stress
Newly diagnosed patients with cancer experienced improvements in quality of life and lower levels of distress by participating in a web-based stress management program, according to results of a study presented at the 2017 ASCO Annual Meeting.
Testicular Cancer Survivors Face Health Risks From Low Testosterone
Nearly 40% of testicular cancer survivors had low testosterone levels, leading to a greater likelihood of chronic health problem compared with survivors with normal testosterone levels, according to study findings released at the 2017 ASCO Annual Meeting.
CALM Psychotherapy Eases Depression and Distress in Patients With Advanced Cancer
Advanced cancer exacts an overwhelming emotional toll, and a brief but novel psychological intervention involving individual therapy sessions delivered by trained therapists has been shown to alleviate patients’ distress and help them to manage the profound and practical problems that come with this diagnosis.
Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments
The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.
Single Dose of Radiation as Effective as 5-Day Course for Maintaining Mobility in Patients with Spinal Cord Compression
Results from a large, phase III trial showed that a single radiation treatment relieves symptoms of spinal cord compression in patients with advanced cancer as effectively as a multifractional course of radiotherapy (RT)
Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention
Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.
Ribociclib Benefit in Breast Cancer Sustained With Longer Follow-Up
Frontline treatment with ribociclib plus letrozole improved progression-free survival by 9.3 months compared with letrozole plus placebo for patients with postmenopausal HR-positive, HER2-negative advanced breast cancer.
ASCO 2017: Oncology Leaders Pick Their Top Abstracts
Key opinion leaders spoke with
to share the top-5 abstracts they find to be the most exciting and/or potentially practice-changing across breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, hematologic malignancies, and supportive care being presented at the 2017 ASCO Annual Meeting.
Adjuvant Gefitinib Delays Recurrence in EGFR+ NSCLC
Adjuvant gefitinib reduced the risk of disease recurrence by 40% versus standard chemotherapy in patients with
-positive non–small cell lung cancer, study reports.
Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer
Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.
HPV Vaccine Reduced High-Risk Oral Infections by Nearly 90%, but Poor Uptake Limits Impact
The efficacy of the human papillomavirus vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.
Affordable Care Act Positively Affects Stage at Diagnosis
More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.
Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk
Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.
Adjuvant Capecitabine Improves Survival in Biliary Tract Cancer
Treatment with adjuvant capecitabine improved overall survival by 15 months compared with observation alone for patients with macroscopically resected biliary tract cancer, according to findings from the phase III BILCAP study released in advance of the 2017 ASCO Annual Meeting.
FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More
Neoadjuvant Immunotherapy Emerges as a New Frontier
FDA Grants Full Approval to Pembrolizumab Plus Chemo for NSCLC
Master of the Whipple Gave Hope, Extended Lives
FDA Approves Nivolumab for Small Cell Lung Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.